Core Insights - DBV Technologies has successfully completed the patient screening for the VITESSE Phase 3 clinical trial, which evaluates the Viaskin® Peanut Patch in children aged 4 to 7 with peanut allergies [1][2] - The VITESSE trial is the largest immunotherapy clinical trial for this demographic, involving over 600 subjects across 86 sites in multiple countries [2] - Topline results from the VITESSE study are anticipated by Q4 2025 [1] Company Overview - DBV Technologies is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immunologic conditions [3] - The company utilizes its proprietary Viaskin technology platform to address food allergies through epicutaneous immunotherapy (EPIT™), which aims to desensitize the immune system to allergens [3] - DBV is committed to transforming the care of individuals with food allergies, with ongoing clinical trials for Viaskin Peanut targeting both toddlers and children [3] Operational Highlights - The VITESSE Phase 3 trial is a 12-month study designed to evaluate the efficacy and safety of the Viaskin Peanut Patch [2] - The trial has achieved enrollment ahead of schedule, closing screening a month earlier than expected [2] - DBV Technologies is headquartered in Châtillon, France, with operations in North America [4]

Châtillon, France, September 4, 2024 DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that Daniel Tassé, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024, at 3:00 pm ET, in New York City. A live webcast of the present ...

Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 07/31/2024 96,498,927 Total gross of voting rights: 96,498,927 Total net* of voting rights: 96,214,457 * Net total = total number of voting rights attached to shares – shares without voting rights At ...

DBV Technologies S.A. (NASDAQ:DBVT) Q2 2024 Earnings Conference Call July 30, 2024 5:30 PM ET Company Participants Katie Matthews – Investor Relations Daniel Tassé – Chief Executive Officer Pharis Mohideen – Chief Medical Officer Virginie Boucinha – Chief Financial Officer Conference Call Participants Jon Wolleben – Citizens JMP Operator Welcome to the DBV Second Quarter Financial Results and Business Update Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today ...

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbvtechnologies.com) in the section Investors/Financial Information, and on the AMF website (www.amffrance.org), in French only. by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; by email: investors@dbv-technologies.com. DBV Technologies is a clinical-stage biopharmaceutical com ...

DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report The 2024 Half-Year Report can be consulted or downloaded from the Company's website (www.dbvtechnologies.com) in the section Investors/Financial Information, and on the AMF website (www.amffrance.org), in French only. by mail : DBV Technologies – 107 avenue de la République 92320 Châtillon, France ; by email: investors@dbv-technologies.com. DBV Technologies is a clinical-stage biopharmaceutical com ...

Exhibit 99.1 • VITESSE enrollment in peanut allergic 4-7-year-olds is on-track and recruitment is expected to be complete by end of Q3 2024 • DBV submitted a labeling proposal, informed by the EPITOPE efficacy data, to the Food and Drug Administration (FDA) to address the FDA's protocol queries regarding patch wear-time in COMFORT Toddlers • DBV closes Q2 2024 with a cash balance of $66.2 million; due to cost-saving measures, the Company's cash runway is extended into Q1 2025 COMFORT Toddlers "On April 29th ...

The Company has incurred operating losses and negative cash flows from operations since inception. As of July 30th, DBV's available cash and cash equivalents are not projected to be sufficient to support the Company's operating plan for at least the next 12 months. As such, there is substantial doubt regarding its ability to continue as a going concern. The Company intends to seek additional capital as it continues research and development efforts and prepares for the launch of Viaskin Peanut, if approved. ...

DBV Technologies S.A. (Registrant) | --- | --- | --- | |-------|----------------------------------------------------------------------------------------------------------|-------| | By: | /s/ Daniel Tassé | | | | Daniel Tassé | | | | Chief Executive Of icer (Principal Executive Of icer) | | | By: | /s/ Virginie Boucinha | | | | Virginie Boucinha Chief Financial Of icer (Principal Financial and Accounting Of icer) | | Date: July 30, 2024 24 See "Note 2: Significant Events and Transactions – Legal Proceedings ...

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to review its second quarter 2024 financial results and provide a business update. DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company's ordinary shares are traded on segment B of Euronext Paris (Tick ...